Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an announcement.
Shanghai Henlius Biotech, Inc. announced the composition of its board of directors and their respective roles within the company. This announcement outlines the leadership structure, which is crucial for stakeholders to understand the governance and strategic direction of the company. The board includes a mix of executive, non-executive, and independent non-executive directors, indicating a diverse leadership team poised to guide the company in its industry pursuits.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of monoclonal antibody drugs. The company operates in the pharmaceutical industry, with a market focus on providing innovative and affordable biologic medicines.
YTD Price Performance: 28.69%
Average Trading Volume: 1,441,157
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.58B
Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.